Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ: FULC) will release its third quarter 2025 financial results on Wednesday, October 29, 2025, before U.S. markets open.

Management will host a conference call and webcast on October 29, 2025 at 8:00 a.m. ET to discuss results and provide a corporate update. Participants must register to receive dial-in details and a unique PIN. An audio webcast will be available on the company’s Investor Relations website and an archived replay will be posted after the live webcast.

News Market Reaction

-6.80%

1 alert

-6.80% News Effect

-$35M Valuation Impact

$484M Market Cap

0.8x Rel. Volume

On the day this news was published, FULC declined 6.80%, reflecting a notable negative market reaction. This price movement removed approximately $35M from the company's valuation, bringing the market cap to $484M at that time.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When will Fulcrum Therapeutics (FULC) report Q3 2025 results?

Fulcrum will release Q3 2025 results on October 29, 2025 before U.S. markets open.

What time is the Fulcrum Therapeutics Q3 2025 conference call and webcast?

The conference call and webcast will begin at 8:00 a.m. ET on October 29, 2025.

How do investors register for the Fulcrum Therapeutics October 29, 2025 call?

Investors must register via the company’s event link to receive dial-in details and a unique PIN.

Where can I listen to the Fulcrum Therapeutics Q3 2025 webcast?

The audio webcast will be available on Fulcrum’s Investor Relations website at www.fulcrumtx.com.

Will the Fulcrum Therapeutics Q3 2025 presentation be available after the live event?

Yes. An archived replay of the webcast will be posted on the Investor Relations website after the live event.

Will Fulcrum discuss clinical updates during the October 29, 2025 call?

Management said the call will cover results and provide an update on recent corporate developments, which may include clinical updates.